U.S. markets close in 3 hours 36 minutes

Ocuphire Pharma, Inc. (OCUP)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
4.3600-0.0600 (-1.36%)
As of 12:16PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Williams %R

Williams %R

Previous Close4.4200
Open4.4200
Bid4.3500 x 900
Ask4.3900 x 3100
Day's Range4.3301 - 4.4441
52 Week Range3.6800 - 13.8100
Volume48,097
Avg. Volume1,490,407
Market Cap68.194M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Ocuphire Announces Publication in the Journal of Cellular Signaling Featuring its Oral Ref-1 Inhibitor APX3330 in Phase 2 Trial for the Treatment of Retinal Disease
    GlobeNewswire

    Ocuphire Announces Publication in the Journal of Cellular Signaling Featuring its Oral Ref-1 Inhibitor APX3330 in Phase 2 Trial for the Treatment of Retinal Disease

    Highlights Favorable Safety Profile of the Oral New Chemical Entity APX3330 and Its Novel Anti-Angiogenic and Anti-Inflammatory Mechanism of Action Properties Relevant to a Broad Range of Retinal Diseases Phase 2 Data from ZETA-1 Trial in Diabetic Retinopathy Expected in 2022 FARMINGTON HILLS, Mich., July 22, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of

  • Ocuphire Selected to Present at Multiple Ophthalmic Conferences in July
    GlobeNewswire

    Ocuphire Selected to Present at Multiple Ophthalmic Conferences in July

    Positive Results from Phase 2 Presbyopia (VEGA-1) and Phase 3 Reversal of Mydriasis (MIRA-2) Studies to be Presented at 2021 ASCRS Annual Meeting in Las Vegas Ocuphire Presenting Nyxol® + Low Dose Pilocarpine Phase 2 Data in the Presbyopia Industry Panel at Eyecelerator@ASCRS in Las Vegas Ocuphire to Highlight Novel Refractive and Retinal Approaches in Ophthalmology at Eye on Innovation Demy-Colton Virtual Salon Series FARMINGTON HILLS, Mich., July 13, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma, I

  • Ocuphire Pharma, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    GlobeNewswire

    Ocuphire Pharma, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    FARMINGTON HILLS, Mich., July 09, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), today announced that the Compensation Committee of its Board of Directors, which is composed entirely of independent directors, approved an equity award under Ocuphire’s Inducement Plan, as a material inducement to Amanda Providakes in connection with her employment with the Company effective on July 6, 2021. The equity award was approved in accordance with Nasdaq Listing Rule 5635(c)(4), which also